Cataract is the presence of opacity in the crystalline lens of the eye. It causes painless, progressive blurring of vision.
It is the leading cause of blindness worldwide and the most prevalent ocular disease.
The initiating events that lead to loss of transparency of both the cortical and nuclear lens tissue is the oxidation of the membrane lipids, structural or enzymatic proteins or DNA by peroxidases or free radicals induced by UV light.
Asians who use angiotensin-converting enzyme inhibitors, fibrates, alpha-glucosidase inhibitors or insulin are likely to have cortical cataract, independent of the presence of hypertension, hyperlipidaemia or diabetes, according to data from the Singapore Epidemiology of Eye Diseases (SEED) study.
One in 10 Malay, Indian and Chinese Singaporeans aged ≥40 years undergoes cataract surgery in at least one eye over 6 years, according to data from the Singapore Epidemiology of Eye Diseases (SEED) Study. Diabetes and myopia are modifiable risk factors for cataract prevalence.
An anterior chamber intracameral dexamethasone drug-delivery suspension (IBI-10090) at concentrations of 342 and 517 μg is safe and effective in treating postoperative inflammation in patients undergoing cataract surgery, according to a study. In addition, IBI-10090 may replace corticosteroid drop installation in these patients.
drug applications approved by US FDA as of 1 - 15 February 2018 which includes
Entities (NMEs) and new biologics. It does not include Tentative Approvals.
Supplemental approvals may have occurred since the original approval date.
A novel incentive care scheme (ICS) ─ combining patient education together with social, financial, and logistic support (in the form of transport allowance) ─ was effective at improving compliance of underprivileged elderly people with visual impairment in attending tertiary eye care referrals after community screening, reveals a pilot study.
Immediate sequential (ISBCS) compared with delayed sequential (DSBCS) bilateral cataract surgery does not appear to result in worse postoperative best-corrected visual acuity (BCVA) or refractive error, or with an elevated complication risk, suggests a recent study.
Unusual involvement of the eyes with atypical presentations may occur in patients with inflammatory bowel diseases (IBD) on antitumour necrosis factor (anti-TNF) therapy, according to a recent study presented at the 2019 Advances in Inflammatory Bowel Diseases Annual Meeting (AIBD 2019).